AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win
AbbVie’s preventative migraine therapy, Qulipta (atogepant), has netted a successful late-stage readout in menstrual migraine, potentially poising the drug for…
News
TenNor reports top-line Phase IIa results for rifaquizinone in PJI
Biohaven’s epilepsy drug hit with FDA clinical hold
First healthy volunteers dosed in Bionyra’s Phase I BYN-001 study
BioMarin paints picture of dwarfism drug’s wider efficacy on Phase III win
Beeline Medicines’ Phase II SLE trial of afimetoran meets primary endpoint
Tyra announces initial data from Phase II SURF302 trial of dabogratinib
Pharma’s R&D, commercial approach shifts amid global policy evolution
